Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
E: phak@novonordisk.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
69,260
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,416.60 | 57.70 | -0.68% |
CAC 40 | 7,541.36 | 63.58 | 0.85% |
DAX 40 | 19,120.93 | 105.52 | 0.55% |
Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
FTSE 100 | 8,280.63 | 1.89 | -0.02% |
HKSE | 22,736.87 | 623.36 | 2.82% |
NASDAQ | 18,137.85 | 219.37 | 1.22% |
Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
S&P 500 | 5,751.07 | 51.13 | 0.90% |
S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
SSE Composite Index | 3,336.50 | 248.97 | 8.06% |